Early Tumor Marker Response Predicts Treatment Outcomes in Patients with Unresectable Hepatocellular Carcinoma Receiving Combined Lenvatinib, Immune Checkpoint Inhibitors, and Transcatheter Arterial Chemoembolization Therapy

Early Tumor Marker Response Predicts Treatment Outcomes in Patients with Unresectable Hepatocellular Carcinoma Receiving Combined Lenvatinib, Immune Checkpoint Inhibitors, and Transcatheter Arterial Chemoembolization Therapy

Meng-Chao Luo,1,2,* Jia-Yi Wu,1,3,* Jun-Yi Wu,1,3 Zhong-Tai Lin,1,2 Yi-Nan Li,3 Zhen-Xin Zeng,3 Shao-Ming Wei,1,2 Mao-Lin Yan1,3 1Shengli Clinical Medical College of Fujian Medical University, Fuzhou, Fujian Province, 350001, People’s Republic of China; 2Department of General Surgery...

Cijeli opis

Bibliografski detalji
Glavni autori: Luo MC, Wu JY, Lin ZT, Li YN, Zeng ZX, Wei SM, Yan ML
Format: Članak
Jezik:English
Izdano: Dove Medical Press 2023-10-01
Serija:Journal of Hepatocellular Carcinoma
Teme:
unresectable hepatocellular carcinoma
alpha-fetoprotein
des-gamma-carboxyprothrombin
combination therapy
tumor response
Online pristup:https://www.dovepress.com/early-tumor-marker-response-predicts-treatment-outcomes-in-patients-wi-peer-reviewed-fulltext-article-JHC

Internet

https://www.dovepress.com/early-tumor-marker-response-predicts-treatment-outcomes-in-patients-wi-peer-reviewed-fulltext-article-JHC

Slični predmeti